(Total Views: 275)
Posted On: 06/26/2021 8:33:24 PM
Post# of 653
$NRXP $RLFTF Kpags on Yh0 - NRx Pharmaceuticals and Nephron Pharmaceuticals believe that the mechanism by which aviptadil rapidly degrades in solution has been identified and formulation, manufacturing, and container closure innovations have been developed to counter this degradation.
As of June 15, 2021, NRx Pharmaceuticals has initiated GMP manufacturing of ZYESAMI™ and anticipates a long-term stable formulation that will have the potential to be stockpiled should ZYESAMI™ be deemed safe and effective by the FDA.
From the filing today.
https://ir.stockpr.com/neurorxpharma/sec-fili...615ds1.htm
As of June 15, 2021, NRx Pharmaceuticals has initiated GMP manufacturing of ZYESAMI™ and anticipates a long-term stable formulation that will have the potential to be stockpiled should ZYESAMI™ be deemed safe and effective by the FDA.
From the filing today.
https://ir.stockpr.com/neurorxpharma/sec-fili...615ds1.htm
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)
$MJ